Meaningful changes in end-of-life care among patients with myeloma.

Abstract:

:Patients with advanced myeloma experience a high symptom burden particularly near the end of life, making timely hospice use crucial. Little is known about the quality and determinants of end-of-life care for this population, including whether potential increases in hospice use are also accompanied by "late" enrollment (≤ 3 days before death). Using the Surveillance, Epidemiology, and End-Results-Medicare database, we identified patients ≥ 65 years diagnosed with myeloma between 2000 and 2013 who died by December 31, 2013. We assessed prevalence and trends in hospice use, including late enrollment. We also examined six established measures of potentially aggressive medical care at the end of life. Independent predictors of late hospice enrollment and aggressive end-of-life care were assessed using multivariable logistic regression analyses. Of 12,686 myeloma decedents, 48.2% enrolled in hospice. Among the 6111 who enrolled, 17.2% spent ≤ 3 days there. There was a significant trend in increasing hospice use, from 28.5% in 2000 to 56.5% by 2013 (Ptrend <0.001), no significant rise in late enrollment (12.2% in 2000 to 16.3% in 2013, Ptrend =0.19), and a slight decrease in aggressive end-of-life care (59.2% in 2000 to 56.7% in 2013, Ptrend =0.01). Patients who were transfusion-dependent, on dialysis, or survived for less than one year were more likely to enroll late in hospice and experience aggressive medical care at the end of life. Gains in hospice use for myeloma decedents were not accompanied by increases in late enrollment or aggressive medical care. These findings suggest meaningful improvements in end-of-life care for this population.

journal_name

Haematologica

journal_title

Haematologica

authors

Odejide OO,Li L,Cronin AM,Murillo A,Richardson PG,Anderson KC,Abel GA

doi

10.3324/haematol.2018.187609

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

1380-1389

issue

8

eissn

0390-6078

issn

1592-8721

pii

haematol.2018.187609

journal_volume

103

pub_type

杂志文章
  • Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.

    abstract::CD27, a tumor necrosis factor receptor family member, interacts with CD70 and influences T-, B- and NK-cell functions. Disturbance of this axis impairs immunity and memory generation against viruses including Epstein Barr virus (EBV), influenza, and others. CD27 is commonly used as marker of memory B cells for the cla...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.068791

    authors: Salzer E,Daschkey S,Choo S,Gombert M,Santos-Valente E,Ginzel S,Schwendinger M,Haas OA,Fritsch G,Pickl WF,Förster-Waldl E,Borkhardt A,Boztug K,Bienemann K,Seidel MG

    更新日期:2013-03-01 00:00:00

  • Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.

    abstract::Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of various human cancers. We examined the therapeutic potential of ARV 825 ag...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.201483

    authors: Lim SL,Damnernsawad A,Shyamsunder P,Chng WJ,Han BC,Xu L,Pan J,Pravin DP,Alkan S,Tyner JW,Koeffler HP

    更新日期:2019-06-01 00:00:00

  • Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.

    abstract::The mechanisms of drug resistance in multiple myeloma are poorly understood. Here we show that CD47, an integrin-associated receptor, is significantly upregulated in drug resistant myeloma cells in comparison with parental cells, and that high expression of CD47 detected by immunohistochemistry is associated with shor...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.227579

    authors: Rastgoo N,Wu J,Liu A,Pourabdollah M,Atenafu EG,Reece D,Chen W,Chang H

    更新日期:2020-12-01 00:00:00

  • Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.

    abstract::A probabilistic model was used to compare cryoprecipitate to viral inactivated, commercial fibrinogen concentrate to evaluate with regard to the recipient's risk of exposure to an emergent AIDS-like epidemic. In patients who occasionally need a therapeutic dose of fibrinogen, commercial fibrinogen would be marginally ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.11072

    authors: Pereira A

    更新日期:2007-06-01 00:00:00

  • Thrombolytic therapy for central venous catheter occlusion.

    abstract:BACKGROUND:Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal. DESIGN AND METHODS:This paper reviews thrombolytic treatment for catheter obstruction. Literature from Med...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.2011.050492

    authors: Baskin JL,Reiss U,Wilimas JA,Metzger ML,Ribeiro RC,Pui CH,Howard SC

    更新日期:2012-05-01 00:00:00

  • Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosus.

    abstract::We report on the likely mechanism of an exacerbation of neurological symptoms developed during immune reconstitution after autologous non-myeloablative hematopoietic stem cell transplantation in a 33-year-old man with systemic lupus erythematosus- associated recurrent transverse myelitis. Cerebrospinal fluid examinati...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Muraro PA,Nikolov NP,Butman JA,Abati A,Gea-Banacloche J,Gress R,Lipsky P,Illei G,Pavletic S

    更新日期:2006-06-01 00:00:00

  • Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.

    abstract:BACKGROUND AND OBJECTIVE:Idarubicin (IDA) is relatively immune to the multidrug resistance P-gp mechanism that is frequently expressed in recurrent and refractory hematologic malignancies. Owing to rapid metabolism in vivo, a continuous infusion (CI) of IDA might prolong exposure time to the parent drug rather than its...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bassan R,Chiodini B,Zucchetti M,Lerede T,Cornelli PE,Cortelazzo S,Barbui T

    更新日期:1998-01-01 00:00:00

  • Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

    abstract:BACKGROUND:Mutation C1149R in the von Willebrand factor (VWF) gene has been thought to cause autosomal dominant severe type 1 von Willebrand disease (VWD). DESIGN AND METHODS:Eight patients from three unrelated families with this mutation were included in the present study who had distinct VWF abnormalities, not descr...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2008.003301

    authors: Pérez-Rodríguez A,García-Rivero A,Lourés E,López-Fernández MF,Rodríguez-Trillo A,Batlle J

    更新日期:2009-05-01 00:00:00

  • Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.

    abstract:BACKGROUND AND OBJECTIVES:In March 1987 AIEOP started the AIEOP-ALL-87 study, based on the previous AIEOP-ALL-82. The aim of this new study was to evaluate, for all risk groups: a) the efficacy of treatment intensification achieved by adding a fourth drug (daunomycin) in the induction phase and a 3-drug reinduction pha...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Paolucci G,Vecchi V,Favre C,Miniero R,Madon E,Pession A,Rondelli R,De Rossi G,Lo Nigro L,Porta F,Santoro N,Indolfi P,Basso G,Conter V,Aricò M,Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

    更新日期:2001-05-01 00:00:00

  • Hepcidin demonstrates a biphasic association with anemia in acute Plasmodium falciparum malaria.

    abstract::Hepcidin levels are high and iron absorption is limited in acute malaria. The mechanism(s) that regulate hepcidin secretion remain undefined. We have measured hepcidin concentration and cytokines in 100 Kenyan children with acute falciparum malaria and different degrees of anemia. Hepcidin was increased on admission a...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2012.065854

    authors: Casals-Pascual C,Huang H,Lakhal-Littleton S,Thezenas ML,Kai O,Newton CR,Roberts DJ

    更新日期:2012-11-01 00:00:00

  • The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer.

    abstract:BACKGROUND:The relative efficacy of high-dose chemotherapy (HDC) compared to standard treatment for high-risk primary (HRPBC) or metastatic breast cancer (MBC) constitutes an area of intense controversy among the medical oncology community. A number of randomized trials have been conducted to address this issue. In mos...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Nieto Y

    更新日期:2003-02-01 00:00:00

  • Cell cycle kinetic changes induced by interleukin-3 and interleukin-6 during ex vivo expansion of mobilized peripheral blood CD34 cells.

    abstract::The long-term repopulating capacity of mobilized peripheral blood (MPB) CD34+ cells can be abrogated during ex vivo expansion due to cell-cycle related changes. In this study, we traced cell cycle kinetic and quiescent status of CD34+ cells during ex vivo expansion with exogenous cytokines. The addition of interleukin...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Sanchez-Garcia J,Torres A,Herrera C,Alvarez MA

    更新日期:2006-01-01 00:00:00

  • Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.

    abstract::Central nervous system (CNS) relapse of diffuse large B-cell lymphoma remains uncommon but catastrophic. The benefit of standalone intrathecal prophylaxis in reducing CNS recurrence is unclear and remains controversial. No systematic review analysing the evidence for stand-alone intrathecal prophylaxis has been perfor...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.229948

    authors: Eyre TA,Djebbari F,Kirkwood AA,Collins GP

    更新日期:2020-07-01 00:00:00

  • 11q- and constitutional X trisomy in a patient with M5b acute non-lymphocytic leukemia.

    abstract::A patient with M5b acute nonlymphoblastic leukemia (ANLL) and a 47,XXX del(11) (q23) karyotype is described. Partial remission was obtained after treatment with daunorubicin, arabinosylcytosine and VP-16. Subsequently, two courses of chemotherapy for resistant ANLL were administered without achieving complete remissio...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Bigazzi C,Galieni P,Scarinci R,Vivarelli R,Bucalossi A,Biancolini G,Falbo R,Vessichelli F,Dispensa E

    更新日期:1993-05-01 00:00:00

  • Frequency and distribution of megakaryoblasts in FAB subtypes of ANLL: an immunocytochemical ultrastructural study.

    abstract:BACKGROUND:Identification of early megakaryocyte (MK) precursors is difficult and conflicting. The prevalence of leukemias with a megakaryocytic component may be underestimated when conventional techniques are utilized. The recent development of immuno-ultrastructural procedures for simultaneous detection of platelet p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Tomasi P,Tallarico A,Vasi V,Scapoli G,Castoldi G

    更新日期:1993-03-01 00:00:00

  • Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

    abstract::Krüppel-like factor 4 is a transcription factor with anti-proliferative effects in differentiated cells, but with the ability to reprogram adult cells into cell-cycling pluripotent cells. In cancer, Krüppel-like factor 4 acts as either an anti-oncogene or an oncogene. We analyzed Krüppel-like factor 4 gene expression ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.066944

    authors: Schoenhals M,Kassambara A,Veyrune JL,Moreaux J,Goldschmidt H,Hose D,Klein B

    更新日期:2013-09-01 00:00:00

  • Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.

    abstract::Alemtuzumab serum levels and clinical response after subcutaneous administration (10 mg 3 times/week for six weeks) have been explored in 29 chronic lymphocytic leukemia patients receiving the monoclonal antibody as consolidation. Serum concentrations after each administration gradually increased during the first week...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2010.033159

    authors: Montagna M,Montillo M,Avanzini MA,Tinelli C,Tedeschi A,Visai L,Ricci F,Vismara E,Morra E,Regazzi M

    更新日期:2011-06-01 00:00:00

  • Resolving T-cell receptor clonality in two and genotype in four multiplex polymerase chain reactions.

    abstract:BACKGROUND AND OBJECTIVES:The diagnosis of T-cell neoplasia requires the use of immunohistochemistry on tumor sections or molecular genetic analysis of T-cell receptor (TCR) clonality. Multiplex polymerase chain reactions (PCR) offer a sensitive and expeditious approach to determining clonality early in the diagnostic ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Dictor M,Warenholt J,Isinger A

    更新日期:2005-11-01 00:00:00

  • Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.

    abstract:BACKGROUND:Cutaneous T-cell lymphomas (CTCL) represent about the 80% of skin lymphomas and comprise a heterogeneous group of diseases with respect to clinical presentation, outcome, histologic and immunophenotypic features. In the recent years, data have been accumulated indicating that clinical and biological differen...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Paulli M,Berti E

    更新日期:2004-11-01 00:00:00

  • Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

    abstract::Chronic autoimmune or pathogen-induced immune reactions resulting in lymphoid neogenesis are associated with development of malignant lymphomas, mostly extranodal marginal zone B-cell lymphomas (MZBCLs). In this review we address (i) chemokines and adhesion molecules involved in lymphoid neogenesis; (ii) the autoimmun...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.2009.005983

    authors: Bende RJ,van Maldegem F,van Noesel CJ

    更新日期:2009-08-01 00:00:00

  • Somatic hypermutation signature in B-cell low-grade lymphomas.

    abstract:BACKGROUND:Immunoglobulin gene somatic hypermutation is a biologically relevant and clinically useful prognostic factor in different types of low-grade B-cell lymphomas, including chronic lymphocytic leukemia, mantle cell lymphoma and splenic marginal zone lymphoma. DESIGN AND METHODS:With the aim of identifying surro...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12999

    authors: Tracey L,Aggarwal M,García-Cosio M,Villuendas R,Algara P,Sánchez-Beato M,Sánchez-Aguilera A,García JF,Rodríguez A,Camacho FI,Martínez N,Ruiz-Ballesteros E,Mollejo M,Piris MA

    更新日期:2008-08-01 00:00:00

  • Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias.

    abstract:BACKGROUND AND OBJECTIVES:Levels of intracellular bcl-2 oncoprotein have been found to be increased in leukemic cells of CD5+ B-chronic lymphocytic leukemia (CLL) patients. However, it is not clear whether bcl-2 overexpression is a peculiar feature of CD5+ B-CLL. Based on this background we carried out a quantitative f...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Molica S,Mannella A,Crispino G,Dattilo A,Levato D

    更新日期:1997-09-01 00:00:00

  • In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.

    abstract::Interleukin-10 failed to modify either the percentage of bcl-2+ cells or the number of bcl-2 molecules, or to reduce 2-chlorodeoxyadenosine- and fludarabine-induced apoptosis. The cytokine at 0.1 ng/mL induced an increase of cell survival both in the absence or in the presence of 2-chlorodeoxyadenosine, while no diffe...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Morabito F,Filangeri M,Sculli G,Oliva B

    更新日期:1998-11-01 00:00:00

  • Molecular diagnosis of A gamma hereditary persistence of fetal hemoglobin using polymerase chain reaction and oligonucleotide analysis.

    abstract::By combining the polymerase chain reaction (PCR) of the gamma globin gene promoters with synthetic oligonucleotide analysis we have diagnosed the -196 C----T and the -117 G----A substitutions in heterozygous carriers of non deletional A gamma HPFH from two unrelated Italian families. The identification of the beta-tha...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Gottardi E,Alfarano A,Serra A,Sciarratta G,Bertero MT,Saglio G,Camaschella C

    更新日期:1990-01-01 00:00:00

  • Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

    abstract::We previously reported initial results in 102 multiple myeloma (MM) patients treated with sequential high-dose melphalan and autologous hematopoietic cell transplantation followed by 200 cGy total body irradiation with or without fludarabine 90 mg/m2 and allogeneic hematopoietic cell transplantation. Here we present l...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.200253

    authors: Maffini E,Storer BE,Sandmaier BM,Bruno B,Sahebi F,Shizuru JA,Chauncey TR,Hari P,Lange T,Pulsipher MA,McSweeney PA,Holmberg L,Becker PS,Green DJ,Mielcarek M,Maloney DG,Storb R

    更新日期:2019-02-01 00:00:00

  • Prevalence and patterns of symptomatic thromboembolism in oncohematology.

    abstract:BACKGROUND AND OBJECTIVE:Approximately 15% of patients with cancer will experience a thrombotic episode at some time. Some patients are at particularly high risk depending on the histology of the malignant disease. The aim of the study was to determine the actual prevalence of thrombotic episodes in oncohematologic pat...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Sgarabotto D,Prandoni P,Stefani PM,Scano F,Vianello F,Sartori R,Pietrogrande F,Caenazzo A,Girolami A

    更新日期:1998-05-01 00:00:00

  • Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.

    abstract:BACKGROUND:Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone. DESIGN AND METHODS:In this prospective, multicenter, phase II study, patients with relapsed/refractory mantle cell lymphoma who were not eligible for, or had relap...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2011.051813

    authors: Zaja F,De Luca S,Vitolo U,Orsucci L,Levis A,Salvi F,Rusconi C,Ravelli E,Tucci A,Bottelli C,Balzarotti M,Brusamolino E,Bonfichi M,Pileri SA,Sabattini E,Volpetti S,Monagheddu C,Vacca A,Ria R,Fanin R

    更新日期:2012-03-01 00:00:00

  • Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma.

    abstract::Translocation t(9;14)(p13;q32) involving PAX5 and IGH genes was first described in lymphoplasmacytic lymphoma. New data suggest that this translocation is not restricted to a specific morphologic subtype but occurs in other B-cell lymphomas. We present three cases with a diagnosis of splenic marginal zone lymphoma and...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Baró C,Salido M,Domingo A,Granada I,Colomo L,Serrano S,Solé F

    更新日期:2006-09-01 00:00:00

  • Immobilized fibrinogen activates human platelets through glycoprotein VI.

    abstract::Glycoprotein VI, a major platelet activation receptor for collagen and fibrin, is considered a particularly promising, safe antithrombotic target. In this study, we show that human glycoprotein VI signals upon platelet adhesion to fibrinogen. Full spreading of human platelets on fibrinogen was abolished in platelets f...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2017.182972

    authors: Mangin PH,Onselaer MB,Receveur N,Le Lay N,Hardy AT,Wilson C,Sanchez X,Loyau S,Dupuis A,Babar AK,Miller JL,Philippou H,Hughes CE,Herr AB,Ariëns RA,Mezzano D,Jandrot-Perrus M,Gachet C,Watson SP

    更新日期:2018-05-01 00:00:00

  • Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.

    abstract::In this open label pilot safety study 80 children over 3 months old with deep venous thrombosis were treated with enoxaparin with a target 4 h anti-factor Xa activity between 0.5-0.8 IU/mL. The children were stratified to receive once daily or twice daily doses. The study end-points were post-thrombotic syndrome, re-t...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Schobess R,Düring C,Bidlingmaier C,Heinecke A,Merkel N,Nowak-Göttl U

    更新日期:2006-12-01 00:00:00